Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Trial of RP1 + Nivolumab in Anti-PD1 Failed Melanoma Announced

June 11, 2024

FAILED TRIAL: Confirmatory Ph 3 TROPiCS-04 study in locally advanced/metastatic urothelial cancer (mUC) did not meet the primary endpoint of OS in the ITT population

June 4, 2024

Ph 3 KEYNOTE-522 Trial Met OS Endpoint in Patients With High-Risk Early-Stage TNBC

June 4, 2024

Positive Data Reported from First-in-Human Clinical Study of TTX-MC138

June 3, 2024

Positive Initial Interim Safety and Efficacy Results Announced from RAMP 205 Trial of Avutometinib, Defactinib, Gemcitabine and Nab-paclitaxel combo in 1L Metastatic Pancreatic Cancer​

May 29, 2024

FAILED TRIAL: Datopotamab deruxtecan showed clinically meaningful OS improvement vs. chemo in patients with advanced nonsquamous NSCLC in TROPION-Lung01 Ph 3 trial

May 29, 2024

First Patient dosed in PH-762 Ph 1b Dose-Escalation Study

May 21, 2024

Ph 2/3 Trial of Surufatinib + Camrelizumab combo for 1L Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui Initiated

May 21, 2024

New Long-Term Jelmyto Durability Data and Date for ENVISION Data Announced

May 21, 2024

Updated Clinical Data from Ph 1b Trial of Vepdegestrant + Palbociclib (IBRANCE) Announced

May 21, 2024

VERSATILE-002 Ph 2 Trial Meets Primary Study Endpoints in 1l Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

May 15, 2024

FAILED TRIAL: Ph 3 KEYNOTE-B21 trial of adjuvant KEYTRUDA + chemo +/- RT did not meet primary endpoint of DFS in newly diagnosed, high-risk endometrial cancer after surgery with curative intent

May 15, 2024

Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in interim assessment of Ph 2 GALAXIES Lung-201

May 15, 2024

Positive Ph 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine Announced

May 15, 2024

Higher AML Complete Remission (CR) Rates and Significant Durability Reported with Additional Interim Subject Data

May 15, 2024

Positive Initial Ph 1a Dose Escalation Data for Monotherapy CX-904 Announced

May 14, 2024

Positive topline results of Ph 2 head & neck cancer trial with setanaxib announced

May 14, 2024

Initial Data from Investigator-Initiated Ph 2 Trial of ZYNLONTA® in Patients with R/R MZL Announced

May 14, 2024

FAILED TRIAL: Ph 3 CheckMate -73L trial did not meet primary endpoint of PFS in unresectable, locally advanced stage III NSCLC

May 14, 2024

FAILED TRIAL: Pivotal Ph 3 Study of Uproleselan in R/R AML patients did not meet primary endpoint of OS in the intent-to-treat population

May 14, 2024

Ph 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of OS as 1L Treatment in Patients With HER2+ve Advanced Gastric/GEJ Adenocarcinoma

May 7, 2024

Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Ph 2 Trial in Advanced Ovarian Cancer

May 7, 2024

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

May 7, 2024

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk NMIBC

May 7, 2024

Data from Ph 2 registrational study of the KRAS G12C inhibitor glecirasib reported

May 7, 2024
Page1 … Page11 Page12 Page13 Page14 Page15 … Page30

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.